By Melodie Warner
Illumina Inc. (ILMN) said Teva Pharmaceutical Industries Ltd.
(TEVA) will be the exclusive distributor of the verifi prenatal
test in Israel under a five-year agreement.
Financial terms weren't disclosed.
Illumina paid $350 million in February to buy Verinata Health
Inc., which gave it access to Verinata's verifi prenatal test, the
broadest non-invasive prenatal test currently available for
high-risk pregnancies.
The company said the MOR Institute for Medical Data Ltd.,
through its relationship with Teva, will provide the verifi test to
customers of Clalit Health Services who are at high risk of having
a fetus with a chromosomal abnormality.
The MOR Institute will also establish a 9,000-patient clinical
outcomes registry to collect performance data and will share the
data with Verinata.
Illumina said the patient registry developed through this
collaboration will be the largest and most extensive of its
kind.
Illumina shares closed Friday at $74.84 and were inactive
premarket. The stock is up 35% this year.
Write to Melodie Warner at melodie.warner@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires